Skip to main content

Table 2 Treatment-emergent adverse events reported in ≥2% of patients in any treatment group by dosing interval (safety population)

From: Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Dosing Interval Eptinezumab 100 mg Eptinezumab 300 mg Placebo
Total n = 356 Dose 1 n = 356 Dose 2 n = 348 Total n = 350 Dose 1 n = 350 Dose 2 n = 344 Total n = 366 Dose 1 n = 366 Dose 2 n = 356
Any event, n (%) 155 (43.5) 106 (29.8) 64 (18.4) 182 (52.0) 120 (34.3) 99 (28.8) 171 (46.7) 120 (32.8) 79 (22.2)
 Nasopharyngitis 19 (5.3) 12 (3.4) 6 (1.7) 33 (9.4) 19 (5.4) 7 (2.0) 22 (6.0) 11 (3.0) 11 (3.1)
 URTI 15 (4.2) 5 (1.4) 6 (1.7) 19 (5.4) 8 (2.3) 9 (2.6) 20 (5.5) 13 (3.6) 4 (1.1)
 Migraine 6 (1.7) 1 (0.3) 4 (1.1) 8 (2.3) 2 (0.6) 4 (1.2) 16 (4.4) 6 (1.6) 7 (2.0)
 Nausea 6 (1.7) 4 (1.1) 2 (0.6) 12 (3.4) 10 (2.9) 4 (1.2) 7 (1.9) 4 (1.1) 3 (0.8)
  1. Dosing intervals were not mutually exclusive, meaning that a patient could be counted in both dosing intervals. Italics indicates ≥2% of patients for individual events. URTI upper respiratory tract infection